Clinical Trial Update: Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and hematological activity of AMD3100 (plerixafor) in subjects with renal impairment; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2011-01-12